TabletsMRP Under Process
Official PMBI MRP is being updated for catalog code 2547.
Locate Jan Aushadhi KendraClinical Overview
Entacapone is a reversible, selective, and peripherally acting catechol-O-methyltransferase (COMT) inhibitor. It blocks the conversion of levodopa to 3-O-methyldopa (3-OMD) in peripheral tissues, leading to sustained plasma levodopa concentrations and greater brain bioavailability. Indicated as an adjunct to levodopa and carbidopa for Parkinson's disease patients experiencing end-of-dose motor fluctuations ("wearing-off").
Active Pharmaceutical Ingredients
Verified Clinical References
Usage Guidelines
Take orally simultaneously with each dose of levodopa/carbidopa, up to a maximum of 8 times daily (1600 mg/day), with or without food. Swallow whole.
General Administration Advice: Adhere strictly to the prescribed dosage, frequency, and treatment course. For oral medications, swallow with sufficient water. Never stop antibiotics, psychiatric medications, or antihypertensives abruptly without clinical direction.
Possible Side Effects
Common: Harmless reddish-brown/orange discoloration of urine, dyskinesia, nausea, diarrhea, abdominal pain, dizziness. Rare/Severe: Severe persistent diarrhea/colitis, rhabdomyolysis, and hallucinations.
*Note: Individual physiological responses vary. While many patients experience few or no side effects, notify your treating physician if adverse reactions persist or if hypersensitivity (angioedema, skin rash, dyspnea) occurs.
Precautions & Warnings
Harmless orange-brown urine discoloration occurs in almost all patients. Contraindicated in pheochromocytoma and neuroleptic malignant syndrome history. Discontinue if severe watery diarrhea occurs.
Schedule H (Prescription Required)
This medication is scheduled under statutory drug regulatory frameworks (CDSCO / Drugs & Cosmetics Rules). Dispensing requires a valid medical prescription from a registered medical practitioner. Self-medication or unsupervised dosage adjustment carries significant clinical risks.
Medical Disclaimer: Statutory Clinical Disclaimer: The information provided is for educational and price-transparency purposes only and does not constitute medical advice, clinical diagnosis, or treatment recommendations. Always consult a registered medical practitioner or qualified pharmacist before initiating, modifying, or substituting any medication regimen.
Levodopa 100mg + Carbidopa 25mg + Entacapone 200mg Tablets
Levodopa, Carbidopa, and Entacapone is a triple-combination antiparkinsonian formulation. Levodopa is the metabolic precursor of dopamine that crosses the blood-brain barrier; carbidopa is a peripheral aromatic L-amino acid decarboxylase (DOPA decarboxylase) inhibitor; and entacapone is a reversible peripheral catechol-O-methyltransferase (COMT) inhibitor. Carbidopa and entacapone block both major peripheral metabolic degradation pathways of levodopa, significantly increasing the plasma half-life and brain delivery of levodopa and smoothing out motor fluctuations. Indicated for Parkinson's disease patients experiencing end-of-dose motor fluctuations ("wearing-off").
Levodopa 150mg + Carbidopa 37.5mg + Entacapone 200mg Tablets
Levodopa, Carbidopa, and Entacapone is a triple-combination antiparkinsonian formulation. Levodopa is the metabolic precursor of dopamine that crosses the blood-brain barrier; carbidopa is a peripheral aromatic L-amino acid decarboxylase (DOPA decarboxylase) inhibitor; and entacapone is a reversible peripheral catechol-O-methyltransferase (COMT) inhibitor. Carbidopa and entacapone block both major peripheral metabolic degradation pathways of levodopa, significantly increasing the plasma half-life and brain delivery of levodopa and smoothing out motor fluctuations. Indicated for Parkinson's disease patients experiencing end-of-dose motor fluctuations ("wearing-off").
Levodopa 50mg + Carbidopa 12.5mg + Entacapone 200mg Tablets
Levodopa, Carbidopa, and Entacapone is a triple-combination antiparkinsonian formulation. Levodopa is the metabolic precursor of dopamine that crosses the blood-brain barrier; carbidopa is a peripheral aromatic L-amino acid decarboxylase (DOPA decarboxylase) inhibitor; and entacapone is a reversible peripheral catechol-O-methyltransferase (COMT) inhibitor. Carbidopa and entacapone block both major peripheral metabolic degradation pathways of levodopa, significantly increasing the plasma half-life and brain delivery of levodopa and smoothing out motor fluctuations. Indicated for Parkinson's disease patients experiencing end-of-dose motor fluctuations ("wearing-off").